Literature DB >> 20373694

[Statin prescription in primary prevention: which cardiovascular risk score should be used in Switzerland?].

David Nanchen1, Arnaud Chiolero, Pedro-Manuel Marques-Vidal, Jacques Cornuz, Gérard Waeber, Peter Vollenweider, Nicolas Rodondi.   

Abstract

Primary prevention of cardiovascular disease by physicians is achieved by management of individual risk factors. The eligibility for treatment with statins is based on both an estimate of the risk of developing cardiovascular disease and the LDL-cholesterol. Three risk scores are commonly used: the PROCAM score, the Framingham score, and the European score. In Switzerland, the Swiss Group Lipids and Atherosclerosis (GSLA) recommends to use the PROCAM score with an adjustment of the level of risk for Switzerland. A survey also showed that PROCAM is the most used in Switzerland. In this article, the differences of these scores and their practical applications regarding the prescription of statins in primary prevention are discussed. The consequences and potential benefits of applying these scores in Switzerland are also discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373694

Source DB:  PubMed          Journal:  Rev Med Suisse        ISSN: 1660-9379


  3 in total

1.  Regional differences in self-reported screening, prevalence and management of cardiovascular risk factors in Switzerland.

Authors:  Pedro Marques-Vidal; Fred Paccaud
Journal:  BMC Public Health       Date:  2012-03-28       Impact factor: 3.295

2.  Prevalence and management of cardiovascular risk factors in Portuguese living in Portugal and Portuguese who migrated to Switzerland.

Authors:  Luís Alves; Ana Azevedo; Henrique Barros; Peter Vollenweider; Gérard Waeber; Pedro Marques-Vidal
Journal:  BMC Public Health       Date:  2015-03-31       Impact factor: 3.295

3.  Comparison of self-perceived cardiovascular disease risk among smokers with Framingham and PROCAM scores: a cross-sectional analysis of baseline data from a randomised controlled trial.

Authors:  Benoît Desgraz; Tinh-Hai Collet; Nicolas Rodondi; Jacques Cornuz; Carole Clair
Journal:  BMJ Open       Date:  2017-01-06       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.